Coeptis Therapeutics Stock price
Is Coeptis Therapeutics a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?
As a Free StocksGuide user, you can view scores for all 9,127 stocks worldwide.
Key metrics
Coeptis Therapeutics Stock Analysis
Analyst Opinions
6 Analysts have issued a Coeptis Therapeutics forecast:
Analyst Opinions
6 Analysts have issued a Coeptis Therapeutics forecast:
Don't miss a Thing! We will send you all news about Coeptis Therapeutics directly to your mailbox free of charge.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Coeptis Therapeutics Stock News
Company Profile
Coeptis Therapeutics Holdings, Inc. is a biopharmaceutical company. It develops innovative cell therapy platforms for cancer that have the potential to disrupt conventional treatment paradigms and improve patient outcomes. The firm's products include CD38-GEAR-NK, CD38-Diagnostic and GEAR-NK Product. The company was founded in 2017 and is headquartered in Wexford, PA.
| Head office | United States |
| CEO | Mr. Mehalick |
| Employees | 5 |
| Founded | 2017 |
| Website | coeptistx.com |


